When was Prism Biolab founded?

Prism Biolab was founded in 2006 and raised its 1st funding round 5 years after it was founded.

Where is Prism Biolab located?

Prism Biolab is headquartered in Yokohama, Japan.

How many employees does Prism Biolab have?

As of Apr 30, 2026, the latest employee count at Prism Biolab is 17.

Is Prism Biolab a funded company?

Prism Biolab is a funded company, having raised a total of $22.9M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 06, 2011.

When was the latest funding round of Prism Biolab?

Prism Biolab's latest funding was a $***** Series C round on Jan 24, 2024, with participation from 1 investor. Its primary sector is Oncology. In Japan, the Oncology sector has seen $21.4M in funding in 2026 to date.

Where does Prism Biolab rank among its competitors?

Prism Biolab ranks 275th amongst 3226 active competitors, of which 1112 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Moderna, which secured $590M in Jan, 2025.

Who are the top competitors of Prism Biolab?

Prism Biolab's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Moderna secured the most recent funding round in January, 2025.

Prism Biolab - 2026 Company Profile, Team, Funding & Competitors

Company Details

Prism Biolab is a Japanese, clinical stage biotech developing small molecule therapeutics for cancer and fibrotic diseases. The company develops targeted therapeutics based on its proprietary platform technology. Their platform is focused on the discovery of small molecules that target intracellular protein-protein interactions, based on Helix structures of proteins. Its pipeline includes candidates (PRI-724) that target the Wnt/β-catenin signaling pathway, and are in clinical testing (in partnership with Eisai) for pancreatic cancer, colorectal cancer, leukemia, and HCV - induced cirrhosis. PRI-724 selectively inhibits the CBP/β-catenin complex and modulates the β-catenin dependent pathway of Wnt signaling.

Key Metrics

Founded Year

2006

Location

Yokohama, Japan

Stage

Public

Total Funding

$22.9M in 4 rounds

Latest Funding Round

Series C, Jan 24, 2024, $*****

Investors

Daiwa Corporate Investment & 9 more

Ranked

275^th among 3226 active competitors

Employee Count

17 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2967 more

Exit Details

Public

View Prism Biolab's full profile

Prism Biolab got listed on Jul 02, 2024.

Click here to take a look at Prism Biolab's IPO in detail

Prism Biolab has raised a total funding of $22.9M over 4 rounds. Its first funding round was on May 06, 2011. Its latest funding round was a Series C round on Jan 24, 2024 for $*****. 1 investor participated in its latest round. Prism Biolab has 10 institutional investors.

Here is the list of recent funding rounds of Prism Biolab:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 24, 2024	6219915	Series C	9075359	8581425	6547213	7925291
Sep 13, 2021	7450662	Series C	3272453	3541902	1787218	DBJ Capital & 3 more
May 24, 2013	5592055	Series A	3599094	5650296	3702900	DBJ Capital

Access funding benchmarks and valuations. Sign up today!

View details of Prism Biolab's funding rounds and investors

Prism Biolab's employee count trend

Prism Biolab has 17 employees as of Apr 26. Here is Prism Biolab's employee count trend over the years:

Uncover Prism Biolab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prism Biolab include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Prism Biolab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
5th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
275th	Prism Biolab 2006, Yokohama (Japan), Public	Japanese, clinical stage biotech developing small molecule therapeutics for cancer and fibrotic diseases.	$22.9M	Newton Biocapital, Eisai Innovation & 8 others	58/100